Exosome-Based Detection of EGFR T790M in Plasma from Non-Small Cell Lung Cancer Patients.

@article{CastellanosRizaldos2018ExosomeBasedDO,
  title={Exosome-Based Detection of EGFR T790M in Plasma from Non-Small Cell Lung Cancer Patients.},
  author={Elena Castellanos-Rizaldos and Dominik G Grimm and Vasisht Tadigotla and James Hurley and John Healy and Patricia L Neal and Mia Sher and Raajdeep Venkatesan and Chris A. Karlovich and Mitch Raponi and Anne Krug and Mikkel Noerholm and Jihane Tannous and Bakhos A. Tannous and Luis E Raez and Johan K Skog},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2018},
  volume={24 12},
  pages={
          2944-2950
        }
}
Purpose: About 60% of non-small cell lung cancer (NSCLC) patients develop resistance to targeted epidermal growth factor receptor (EGFR) inhibitor therapy through the EGFR T790M mutation. Patients with this mutation respond well to third-generation tyrosine kinase inhibitors, but obtaining a tissue biopsy to confirm the mutation poses risks and is often not feasible. Liquid biopsies using circulating free tumor DNA (cfDNA) have emerged as a noninvasive option to detect the mutation; however… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 7 times. VIEW TWEETS

From This Paper

Figures, tables, and topics from this paper.

Similar Papers

Loading similar papers…